Bank of America Corp DE Has $3.43 Million Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Bank of America Corp DE lifted its stake in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 48,165.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 499,066 shares of the company's stock after buying an additional 498,032 shares during the period. Bank of America Corp DE owned about 1.67% of Silence Therapeutics worth $3,434,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SLN. JPMorgan Chase & Co. acquired a new stake in Silence Therapeutics during the 4th quarter valued at $26,000. Barclays PLC grew its holdings in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at $69,000. Virtus ETF Advisers LLC raised its holdings in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after buying an additional 6,098 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in Silence Therapeutics during the 4th quarter worth about $113,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. BMO Capital Markets lowered their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Chardan Capital lowered their price objective on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group cut their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a research report on Friday, May 9th. Morgan Stanley reduced their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $33.83.

Silence Therapeutics Price Performance

SLN traded up $0.09 during mid-day trading on Wednesday, hitting $5.50. The stock had a trading volume of 61,247 shares, compared to its average volume of 302,938. The stock's fifty day simple moving average is $3.74 and its 200-day simple moving average is $5.07. The firm has a market capitalization of $164.62 million, a price-to-earnings ratio of -3.50 and a beta of 1.41. Silence Therapeutics plc has a 1-year low of $1.97 and a 1-year high of $22.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. As a group, research analysts expect that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.